Inebilizumab-Cdon

Introduction Overview

Generic Name

inebilizumab-cdon

Brand Name

Uplizna

Dosage Form

Injection for intravenous use (100 mg/10 mL)

Drug Class

Selective immunosuppressants (CD19-directed cytolytic antibody)

Pharmacokinetics

Absorption:
Inebilizumab-cdon, marketed as Uplizna, is administered intravenously, resulting in complete bioavailability since it is directly delivered into the systemic circulation. The drug is given as an infusion typically lasting approximately 90 minutes, which ensures controlled and steady systemic exposure. Because it bypasses gastrointestinal absorption, typical variability associated with oral absorption is not seen, and onset of pharmacodynamic effects is more predictable. Peak plasma concentrations are achieved at the end of the infusion period.

Distribution:
As a large monoclonal antibody of approximately 146 kDa, inebilizumab distributes primarily within the vascular and interstitial compartments. Its volume of distribution is low, consistent with limited extravascular penetration characteristic of monoclonal antibodies. Inebilizumab targets CD19-expressing B cells in circulation and lymphoid tissues. The extent of tissue penetration is sufficient to access lymphoid organs where B cells reside. Binding to CD19-positive B lymphocytes facilitates targeted pharmacological activity. The drug does not significantly cross the blood-brain barrier, limiting direct CNS exposure, which is relevant for its use in neuromyelitis optica spectrum disorder.

Metabolism:
Inebilizumab undergoes catabolism via proteolytic degradation pathways common to endogenous immunoglobulins and therapeutic monoclonal antibodies. It is broken down into small peptides and amino acids by the reticuloendothelial system and cellular proteases. There is no involvement of hepatic cytochrome P450 enzymes since monoclonal antibodies are neither substrates nor inhibitors of these enzymes. The metabolism is not subject to hepatic enzyme induction or inhibition, reducing the potential for metabolic drug interactions.

Elimination:
The elimination half-life of inebilizumab is approximately between 18 to 22 days, typical of humanized monoclonal antibodies. The clearance occurs primarily through catabolic degradation rather than renal excretion, as the molecular size precludes glomerular filtration. Target-mediated drug disposition contributes to clearance through binding and internalization by CD19-expressing B cells, followed by lysosomal degradation. Because the drug depletes B cells, the clearance rate may change over time with prolonged treatment. No dose adjustments are currently recommended based on renal or hepatic impairment due to non-involvement of these organs in drug clearance. Clinical trials have ensured dosing regimens account for these pharmacokinetic properties, supporting administration every 6 months after initial loading doses.

Dosage Forms

Available Dosage Forms:
Uplizna is supplied as a sterile, preservative-free solution in a single-dose vial for intravenous infusion. The concentration is 100 mg per 10 mL (10 mg/mL). Before administration, the drug must be diluted in 250 mL of 0.9% Sodium Chloride solution to ensure appropriate infusion volume and rate.

Dosages for Adults and Adolescents:
- Initial dosing regimen for adults with neuromyelitis optica spectrum disorder (NMOSD) or immunoglobulin G4-related disease (IgG4-RD) involves two intravenous infusions of 300 mg each, administered two weeks apart.
- Subsequent maintenance dosing consists of a 300 mg intravenous infusion every six months, beginning six months after the first infusion.
- Each infusion is administered over approximately 90 minutes, with patient monitoring during and for at least one hour post-infusion to observe for infusion reactions.

Specific Patient Populations:
- Pediatric patients: Safety and efficacy have not been established; use is not recommended in children.
- Renal or hepatic impairment: No dosage adjustment recommended as pharmacokinetics are unaffected by renal or hepatic dysfunction.
- Pregnant or breastfeeding patients: Safety has not been established; females are advised to use effective contraception during treatment and for at least six months after the last dose.
- Patients with risk of infections, hepatitis B virus carriers, or those with latent tuberculosis require thorough screening and monitoring prior to and during treatment.
- Premedication with corticosteroids, antihistamines, and acetaminophen is recommended before infusion to minimize the risk of infusion-related reactions.

Mechanism Of Action

Uplizna (inebilizumab-cdon) is a humanized monoclonal antibody that selectively targets the CD19 antigen, a transmembrane glycoprotein expressed on the surface of B lineage cells from early pre-B cells through mature B cells, but not on plasma cells. By binding to CD19, Uplizna facilitates the depletion of these B cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) mechanisms. This targeted cytolysis reduces pathogenic B cell populations that contribute to autoimmune inflammation.

The drug’s mechanism is critical in diseases like neuromyelitis optica spectrum disorder (NMOSD), which is characterized by autoantibody-mediated damage involving pathogenic B cells. By depleting CD19-positive B cells, Uplizna reduces the population of autoreactive B cells responsible for generating anti-aquaporin-4 (AQP4) antibodies, which are implicated in disease pathogenesis. Hence, modulation of B cell-mediated immunity suppresses the aberrant immune responses that lead to CNS demyelination and inflammation.

Unlike anti-CD20 therapies that target a subset of B cells, CD19 is expressed more broadly across B cell development stages, allowing Uplizna to achieve more comprehensive B cell depletion, including plasmablasts that may escape CD20-targeted agents. This broader targeting may result in greater suppression of autoantibody production.

Clinical trials have demonstrated that Uplizna leads to prolonged depletion of B cells correlating with sustained clinical efficacy in reducing relapse rates in NMOSD and improving outcomes in IgG4-related disease. The drug’s mechanism also implies a risk of increased susceptibility to infections due to the reduced capacity to mount humoral immune responses, necessitating careful patient monitoring and screening before therapy initiation.

Pharmacological Actions

Selective depletion of CD19-positive B lymphocytes via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Immunosuppressive modulation reducing pathogenic autoantibody production in autoimmune disorders.
Targeted cytolytic activity leads to long-lasting B cell depletion impacting disease activity in NMOSD and IgG4-RD.
Modulation of humoral immune responses by reducing B cell populations involved in antigen presentation and antibody secretion.
Suppresses autoimmune inflammation through B cell-mediated mechanisms.
Exhibits slower clearance and prolonged half-life consistent with monoclonal antibodies.
Reduced binding to plasma cells limits immunoglobulin reduction compared to broader B cell depleting agents.
Minimal off-target effects due to high specificity for CD19 antigen.
Does not inhibit cytochrome P450 enzymes or major drug metabolizing pathways.
Requires premedication to mitigate infusion-related immunologic reactions.
May affect immune surveillance, increasing susceptibility to infections including hepatitis B reactivation and PML.
Impacts adaptive immunity through selective B cell depletion while sparing other immune cells.
Does not cross the blood-brain barrier in significant amounts but modulates systemic B cell activity affecting CNS autoimmunity.
Demonstrates dose-dependent pharmacodynamics correlating with B cell counts and clinical efficacy.

Therapeutic Or Clinical Uses

Treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive.
Management of immunoglobulin G4-related disease (IgG4-RD) in adult patients.
Immunomodulation and B cell depletion in autoimmune conditions mediated by pathogenic B cells.
Reduction in relapse rates and disability progression in NMOSD patients.
Therapeutic option for patients who are intolerant or unresponsive to other immunosuppressants targeting CD20.
Maintenance therapy following initial induction dosing to sustain B cell depletion.
Off-label consideration in other CD19-expressing B cell mediated autoimmune disorders pending further research.
Use in combination with other immunosuppressive agents under clinical guidance.
Mitigation of antibody-mediated CNS demyelination through targeted B cell elimination.
Potential incorporation into treatment regimens aiming for steroid-sparing effects in IgG4-RD.
Treatment tailored based on seropositivity for AQP4 antibodies enhancing patient selection.
Use under strict monitoring to prevent serious infections and infusion reactions.

Side Or Adverse Effects

Urinary tract infections, commonly reported in patients treated for NMOSD and IgG4-RD.
Joint pain (arthralgia) occurring as a frequent adverse event during therapy.
Occasional low white blood cell counts (leukopenia) affecting immune defense.
Infusion-related reactions including headache, nausea, sleepiness, shortness of breath, fever, muscle aches, rash, and palpitations.
Serious anaphylactic reactions requiring prompt medical intervention and infusion discontinuation.
Risk of hepatitis B virus (HBV) reactivation in carriers leading to severe liver complications.
Potential for progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection.
Elevated risk of other serious infections due to immunosuppression, including tuberculosis reactivation.
Hypersensitivity reactions during or after infusion despite premedication.
Transient or sustained reduction in immunoglobulin levels over long-term use.
Commonly observed mild to moderate adverse effects generally manageable with supportive care.
Potential injection site or infusion site reactions, such as erythema or swelling.
Laboratory abnormalities including neutropenia and lymphopenia.
Possible fatigue and malaise associated with treatment initiation and dosing.
Unknown long-term carcinogenic or immunogenicity risks necessitating surveillance.

Precautions

Screen patients for active infections before initiating treatment with Uplizna.
Perform baseline testing for hepatitis B virus infection due to risk of reactivation.
Assess for latent or active tuberculosis prior to therapy initiation.
Avoid use in patients with life-threatening infusion reactions to previous Uplizna administration.
Monitor blood cell counts regularly during and after treatment to detect cytopenias.
Premedicate with corticosteroids, antihistamines, and acetaminophen to reduce infusion reactions.
Use contraception in females of reproductive potential during treatment and for six months post last infusion.
Screen for and manage infections promptly during therapy.
Cautiously consider use in patients receiving other immunosuppressive therapies to reduce additive immunosuppression.
Delay non-essential live or live attenuated vaccines during therapy and for an appropriate interval post-therapy.
Exercise caution when treating patients with impaired immune systems or history of recurrent infections.
Ensure patient education on signs and symptoms of infusion reactions and infection.
Pregnancy registry enrollment is encouraged for exposed women to monitor maternal and fetal outcomes.
Breastfeeding safety has not been established; evaluate risk-benefit on a case-by-case basis.
Regular neurologic assessments to detect early signs of PML in at-risk individuals.

Warnings

Risk of serious infusion reactions, including anaphylaxis, necessitating infusion monitoring and readiness for emergency intervention.
Potential for serious infections due to immunosuppression including bacterial, viral, and opportunistic infections.
Reactivation of hepatitis B virus which may result in liver failure or death.
Development of progressive multifocal leukoencephalopathy (PML), a rare viral brain infection leading to severe disability or death.
Risk of tuberculosis reactivation requiring screening and appropriate prophylaxis prior to therapy.
Live vaccines are contraindicated during therapy and for an appropriate period afterward to avoid vaccine-derived infection.
Unknown safety profile in pediatric populations; not recommended for use in children.
Potential for prolonged immunosuppression beyond dosing intervals.
Risk of lowered blood cell counts requiring monitoring to prevent severe cytopenias.
Immunogenicity may develop, although clinical impact remains unclear.
Pregnancy-related risks unknown; use only if clearly indicated and monitor closely.
Risk of fetal exposure necessitates careful pregnancy planning and monitoring.
Risk of hypersensitivity reactions despite premedication protocols.
Potential drug interactions with other immune-modulating therapies.
Delayed immune reconstitution may occur after treatment discontinuation.

Contraindication

History of life-threatening infusion reaction to Uplizna.
Active hepatitis B virus infection at the time of planned treatment initiation.
Active or untreated latent tuberculosis infection.
Known hypersensitivity to inebilizumab or any excipients in the formulation.
Severe active infections contraindicating immunosuppressive therapy.
Concurrent use with live or live attenuated vaccines.
Known immunodeficiency syndromes where immunosuppression is contraindicated.
Pregnancy unless potential benefits outweigh potential risks.
Patients unable to comply with monitoring and safety procedures for infusion reactions.
Use in pediatric patients due to lack of established safety and efficacy.
Hypersensitivity to components such as polysorbate 80 or other inactive ingredients.
Severe neutropenia or leukopenia prior to treatment initiation.
Uncontrolled systemic infections at baseline.
Concurrent treatment with other B-cell depleting agents without clear clinical indication.
Severe hypersensitivity to monoclonal antibody therapies.

Drug Interactions

Concomitant use with immunosuppressive agents such as chemotherapy drugs, corticosteroids, and transplant rejection prophylaxis may increase infection risk.
Potential additive immunosuppressive effects when combined with other biologics targeting B or T cells.
No significant cytochrome P450-mediated metabolic interactions as Uplizna is not metabolized by hepatic enzymes.
Avoid live vaccines during and following treatment due to impaired vaccine response and risk of infection.
No known direct pharmacokinetic interactions with commonly used medications.
Potential enhancement of infusion reaction risk when combined with other monoclonal antibodies.
Caution when co-administered with drugs that modify immune function or hematopoiesis.
No data on interactions with herbal supplements or over-the-counter vitamins; clinical vigilance recommended.
Drugs that affect B cell populations may alter pharmacodynamic response to Uplizna.
Ongoing monitoring advised with polypharmacy involving immunomodulators to mitigate infection risk.
Avoid concomitant use with live vaccines to prevent vaccine-derived infection.
Overlap with other immunosuppressants may require adjustment of treatment regimens.
Potential interaction with antivirals during treatment of hepatitis B reactivation.
Interaction potential exists with drugs affecting complement pathways theoretically but not clinically observed.
No known significant interactions affecting Uplizna efficacy or toxicity identified in current literature.

Preparations Of The Drug

Uplizna is available as a sterile, preservative-free solution in a single-dose vial containing 100 mg in 10 mL (10 mg/mL).
Requires dilution in 250 mL of 0.9% Sodium Chloride injection prior to intravenous infusion.
Administered intravenously over approximately 90 minutes in a clinical setting.
Premedication with corticosteroids, antihistamines, and acetaminophen recommended to reduce infusion reactions.
Supplied by Amgen with strict storage conditions consistent with monoclonal antibody products.
Each vial is for single use only; unused portions must be discarded to maintain sterility.
Incompatible with other intravenous medications and must be infused separately.
Dosing regimen involves an initial two 300 mg infusions given two weeks apart, followed by 300 mg every six months as maintenance.
Must be handled with appropriate aseptic technique to prevent contamination.
No generic or biosimilar currently available; Uplizna is a proprietary monoclonal antibody product.
Storage at refrigerated temperatures (2°C to 8°C) is recommended; do not freeze.
Protect from light and avoid agitation to maintain product integrity.
Preparation must be done by trained healthcare professionals experienced in monoclonal antibody administration.
Disposal should comply with local regulations for biological agents.
Patient monitoring post-infusion is mandatory for at least one hour to observe for adverse reactions.